A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab
Journal of Immunotherapy. 2021; 00: 000-000
A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors
International Immunopharmacology. 2022; 108: 108775. doi: 10.1016/j.intimp.2022.108775
A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan
Frontiers in Medicine. 2023; 10: 1293397. doi: 10.3389/fmed.2023.1293397
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modeling and simulation
European Journal of Cancer. 2020; 131; 68-75
Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation
JAMA Oncol. 2022; 8(11): 1663-1667
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
Current Oncology. 2022; 29(11): 8686-8692
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens with Survival Outcomes in Advanced Non-small cell Lung Cancer
Clinical Lung Cancer. 2021; 22(3): e379-389
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study
ESMO Open 2023; 8(6):102070. doi: 10.1016/j.esmoop.2023.102070
Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question
Clinical and translational oncology. 2021; 23(8): 1511-1519
Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study
Journal of Clinical Oncology. 2022 ASCO Annual Meeting. Abstract 2595
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
Frontiers of Oncology. 2020; 10(1193): 1-9
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
2024; 130(11): 1866-1874
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Journal for Immunotherapy of Cancer. 2024; 12(3): e008325.doi: 10.1136/jitc-2023-008325
Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen
2021; 10(4): 1917-1923
Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic
2023; 83:101004. doi: 10.1016/j.resmer.2023.101004
KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma
Journal of Clinical Oncology. 2021 ASCO Annual Meeting. Abstract 9541
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Annals of Oncology. 2019; 30(4): 644-651
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
JAMA Network Open. 2023; 6(2): e230490. doi:10.1001/jamanetworkopen.2023.0490
Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic
2022; 23(2): 143-150
Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC
Journal of Thoracic Oncology. 2023; 18(2): e14-e16
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
Journal of National Cancer Institute. 2023; 00(0): 1-9
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
AME Clinical Trials Review. 2024; 2: 17
When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents
Targeted Oncology. 2022; 17(3): 253-270
